Malaysian Psychiatric Association - click for home
Malaysian Psychiatric Association
    About Us | Join Us | Contact Us
Search: 
 
  Home »  News & Updates »
 
» About MPA
» President's Message
» In the Press
» Misconceptions
» Mental Health
» Mental Disorders
» Children & Adolescent
» Support & Caring
» Circle of Care
» Upcoming Events
» Early Career Psychiatrist
» Private Psychiatrists
» List of Hospitals
» FAQ
» Interactive Corner
» Newsletters & Bulletins
» Glossary
» Web Resources & Contacts
» Conferences
» Women MH Chapter
» International Society for Bipolar Disorder
» Gallery
» News & Updates
» MPA e-Newsletters
» Materials for Patients
» Announcements
» CPG & Other Guidelines
» MPA Educational Grant
» Advertisements
» Home

 
arrow News & Updates

A Review of The Use of Mirtazapine in Cancer Patients

Date: 18 July 2017

MJP Online Code: MJP-01-08-16

Section: Review Paper

Authors: Syahrir Zaini1,3, Ng Chong Guan1, Ahmad Hatim Sulaiman1, Hasniza Zaman Huri2, Siti Hadijah Shamsudin3

Institutions: 1Department of Psychological Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
2Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
3Department of Pharmacy Practice, Kulliyyah of Pharmacy, International Islamic University Malaysia, Kuantan, Pahang, Malaysia

Keywords: Cancer, Antidepressant, Mirtazapine, Depression, Anxiety, Nausea

Abstract: Introduction: Cancer patients often have concurrent physical and psychological symptoms. These problems may become barriers towards the healing process. Antidepressants seem to be beneficial for the purpose of palliative care in this type of patients. One of the useful medications is mirtazapine, which is known as noradrenergic and specific serotonergic antidepressant (NaSSA). This paper examines the use of mirtazapine in physical and psychological symptoms of cancer patients. Methods: Literature search was done on PubMed (from inception to January 2017) by matching the key terms: ‘noradrenergic and specific serotonergic antidepressants’ or ‘NaSSA’ ‘mirtazapine’ AND ‘cancer’ or ‘oncol*’ or ‘malignancy’ or ‘carcinoma’. Eligible papers were screened at the title and abstract level. Various types of study included in this review, according to certain criteria. Additional papers were also identified by screening of reference lists. Results: A total of twelve papers were reviewed and summarized. Positive findings obtained for the use of mirtazapine in cancer patients associated with various symptoms, including depression, anxiety, cachexia, nausea, hot flashes, and pruritus. Some rare side effects are reported, including constipation, myalgia sedation, dry mouth, stimulation of appetite and weight gain. Conclusion: Mirtazapine has the potential to be beneficial for cancer patients suffering from these physical and psychological symptoms. However, more research studies with sufficient power are warranted to validate the findings.

To read the full paper please visit MPA's Malaysian Journal of Psychiatry (MJP) e-Journal website at www.mjpsychiatry.org


  printer Printer-friendly version   printer Send link to a friend

 
 
| | | |
©Copyright Malaysian Psychiatric Association   2006 - 2011    All rights reserved.
designed & maintained: mobition